The current challenges facing the fields of biological agents and medical therapeutics, such as poor pharmacokinetics and chemoresistance, have necessitated the optimization of therapeutic delivery agents. Among the many platforms being explored, nanodiamonds (NDs) have emerged as promising carriers due to their biocompatibility, scalable synthetic methods, and unique surface-mediated binding of a wide variety of bioactive molecules. ND platforms have also been shown to enhance imaging efficiency, sustain drug release, boost therapeutic efficacy, and improve therapeutic safety profiles. This work addresses recent progress and discusses continued studies toward the potential translation of this unique nanomaterial agent.
Get full access to this article
View all access options for this article.
References
1.
DavisME, ZuckermanJE, ChoiCHJet al.Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 2010; 464:1067–1070.
2.
LiuZ, RobinsonJT, SunXet al.PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc., 2008; 130:10876–10877.
3.
GobinAM, LeeMH, HalasNJet al.Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett., 2007; 7:1929–1934.
ValenciaPM, Hanewich-HollatzMH, GaoWet al.Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials, 2011; 32:6226–6233.
6.
BaiMY, ChengYJ, WicklineSAet al.Colloidal hollow spheres of conducting polymers with smooth surface and uniform, controllable sizes. Small, 2009; 5:1747–1752.
7.
LiuZ, FanAC, RakhraKet al.Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed., 2009; 48:7668–7672.
8.
FerrisDP, LuJ, GothardCet al.Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small, 2011; 7:1816–1826.
9.
MengH, LiongM, XiaTet al.Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-Glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano., 2010; 4:4539–4550.
10.
KostarelosK, LacerdaL, PastorinGet al.Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nano., 2007; 2:108–113.
11.
DanilenkoV. On the history of the discovery of nanodiamond synthesis. Phys Solid State, 2004; 46:595–599.
12.
GreinerNR, PhillipsDS, JohnsonJDet al.Diamonds in detonation soot. Nature, 1988; 333:440.
13.
OsawaE. Single-nano buckydiamond particles. Synthesis strategies, characterization methodologies and emerging applications. HoD. Nanodiamonds: Applications in Biology and Medicine. New York City: Springer, 2010; 1–33.
14.
MochalinVN, ShenderovaO, HoDet al.The properties and applications of nanodiamonds. Nat Nano., 2012; 7:11–23.
15.
Guo-WeiY, Jin-BinW, Qui-XiangL. Preparation of nano-crystalline diamonds using pulsed laser induced reactive quenching. J Phys: Condens Matter, 1998; 10:7923.
ZhangX-Q, LamR, XuXet al.Multimodal nanodiamond drug delivery carriers for selective targeting, imaging, and enhanced chemotherapeutic efficacy. Adv Mater., 2011; 23:4770–4775.
20.
ZhangQ, MochalinVN, NeitzelIet al.Fluorescent PLLA-nanodiamond composites for bone tissue engineering. Biomaterials, 2011; 32:87–94.
21.
WeiL, ZhangW, LuHet al.Immobilization of enzyme on detonation nanodiamond for highly efficient proteolysis. Talanta., 2010; 80:1298–1304.
22.
BalasubramanianG, ChanIY, KolesovRet al.Nanoscale imaging magnetometry with diamond spins under ambient conditions. Nature, 2008; 455:648–651.
23.
ZhangXQ, ChenM, LamRet al.Polymer-functionalized nanodiamond platforms as vehicles for gene delivery. ACS Nano., 2009; 3:2609–2616.
24.
PolandCA, DuffinR, KinlochIet al.Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol., 2008; 3:423–428.
25.
YuSJ, KangMW, ChangHCet al.Bright fluorescent nanodiamonds: No photobleaching and low cytotoxicity. J Am Chem Soc., 2005; 127:17604.
YuanY, WangX, JiaGet al.Pulmonary toxicity and translocation of nanodiamonds in mice. Diam Relat Mater., 2010; 19:291–299.
28.
MohanN, ChenC-S, HsiehH-Het al.In Vivo Imaging and toxicity assessments of fluorescent nanodiamonds in Caenorhabditis elegans. Nano Letters, 2010; 10:3692–3699.
KrügerA, KataokaF, OzawaMet al.Unusually tight aggregation in detonation nanodiamond: Identification and disintegration. Carbon., 2005; 43:1722–1730.
31.
BarnardAS. Self-assembly in nanodiamond agglutinates. J Mater Chem., 2008; 18:4038–4041.
32.
OsswaldS, YushinG, MochalinVet al.Control of sp2/sp3 carbon ratio and surface chemistry of nanodiamond powders by selective oxidation in air. J Am Chem Soc., 2006; 128:11635–11642.
33.
KrugerA, LiangY, JarreGet al.Surface functionalisation of detonation diamond suitable for biological applications. J Mater Chem., 2006; 16:2322–2328.
34.
LiangY, OzawaM, KruegerA. A general procedure to functionalize agglomerating nanoparticles demonstrated on nanodiamond. ACS Nano., 2009; 3:2288–2296.
35.
KruegerA, StegkJ, LiangYet al.Biotinylated nanodiamond: Simple and efficient functionalization of detonation diamond. Langmuir., 2008; 24:4200.
36.
JarreG, LiangY, BetzPet al.Playing the surface game-Diels-Alder reactions on diamond nanoparticles. Chem Commun., 2011; 47:544–546.
37.
MeinhardtT, LangD, DillHet al.Pushing the functionality of diamond nanoparticles to new horizons: orthogonally functionalized nanodiamond using click chemistry. Adv Funct Mater., 2011; 21:494–500.
38.
LiuY, GuZ, MargraveJet al.Functionalization of nanoscale diamond powder: Fluoro-, alkyl-, amino-, and amino acid-nanodiamond derivatives. Chem Mater., 2004; 16:3924.
39.
KruegerA. Diamond nanoparticles: Jewels for chemistry and physics. Adv Mater., 2008; 20:2445–2449.
40.
MochalinVN, GogotsiY. Wet chemistry route to hydrophobic blue fluorescent nanodiamond. J Am Chem Soc., 2009; 131:4594–4595.
41.
FuC-C, LeeH-Y, ChenKet al.Characterization and application of single fluorescent nanodiamonds as cellular biomarkers. Proc Natl Acad Sci., 2007; 104:727–732.
42.
ChangY-R, LeeH-Y, ChenKet al.Mass production and dynamic imaging of fluorescent nanodiamonds. Nat Nano., 2008; 3:284–288.
43.
ChangIP, HwangKC, ChiangCS. Preparation of fluorescent magnetic nanodiamonds and cellular imaging. J Am Chem Soc., 2008; 130:15476.
44.
BradacC, GaebelT, NaidooNet al.Prediction and measurement of the size-dependent stability of fluorescence in diamond over the entire nanoscale. Nano Lett., 2009; 9:3555–3564.
45.
TislerJ, ReuterR, LämmleAet al.Highly efficient FRET from a single nitrogen-vacancy center in nanodiamonds to a single organic molecule. ACS Nano., 2011; 5:7893–7898.
46.
TislerJ, BalasubramanianG, NaydenovBet al.Fluorescence and spin properties of defects in single digit nanodiamonds. ACS Nano., 2009; 3:1959–1965.
47.
BradacC, GaebelT, NaidooNet al.Observation and control of blinking nitrogen-vacancy centres in discrete nanodiamonds. Nat Nano., 2010; 5:345–349.
48.
BarnardAS, SternbergM. Crystallinity and surface electrostatics of diamond nanocrystals. J Mater Chem., 2007; 17:4811–4819.
49.
KorobovMV, AvramenkoNV, BogachevAGet al.Nanophase of water in nano-diamond gel. J Phys Chem C., 2007; 111:7330–7334.
ChenM, ZhangX-Q, ManHBet al.Nanodiamond vectors functionalized with polyethylenimine for siRNA delivery. J Phys Chem Lett., 2010; 1:3167–3171.
54.
AlhaddadA, AdamM-P, BotsoaJet al.Nanodiamond as a vector for siRNA delivery to ewing sarcoma cells. Small, 2011; 7:3087–3095.
55.
ShimkunasR, RobinsonE, LamRet al.Nanodiamond-insulin complexes as pH-dependent protein delivery vehicles. Biomaterials, 2009; 30:5720.
56.
XingY, XiongW, ZhuLet al.DNA damage in embryonic stem cells caused by nanodiamonds. ACS Nano., 2011; 5:2376–2384.
57.
SmithAH, RobinsonEM, ZhangXQet al.Triggered release of therapeutic antibodies from nanodiamond complexes. Nanoscale, 2011; 3:2844–2848.
58.
LiuY, SunK. Protein functionalized nanodiamond arrays. Nanoscale Res Lett., 2010; 5:1045–1050.
59.
LiuK-Ket al.Alpha-bungarotoxin binding to target cell in a developing visual system by carboxylated nanodiamond. Nanotechnology, 2008; 19:205102.
60.
HuangLCL, ChangHC. Adsorption and immobilization of cytochrome c on nanodiamonds. Langmuir., 2004; 20:5879.
61.
ChengC, PerevedentsevaE, TuJet al.Direct and in vitro observation of growth hormone receptor molecules in A549 human lung epithelial cells by nanodiamond labeling. Appl Phys Lett., 2007; 90:163903.
62.
YeapWS, TanYY, LohKP. Using detonation nanodiamond for the specific capture of glycoproteins. Anal Chem., 2008; 80:4659–4665.
63.
PurtovKV, PetuninAI, BurovAEet al.Nanodiamonds as carriers for address delivery of biologically active substances. Nanoscale Res Lett., 2010; 5:631–636.
64.
SheridanC. Gene therapy finds its niche. Nat Biotech., 2011; 29:121–128.
WhiteheadKA, LangerR, AndersonDG. Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov., 2009; 8:129–138.
67.
SmithAM, DuanH, MohsAMet al.Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev., 2008; 60:1226–1240.
68.
GreenwaySE, FillerLE, GreenwayFL. Topical insulin in wound healing: A randomised, double-blind, placebo-controlled trial. J Wound Care, 1999; 8:526–528.
69.
ZhangB, LiY, FangCYet al.Receptor-mediated cellular uptake of folate-conjugated fluorescent nanodiamonds: A combined ensemble and single-particle study. Small, 2009; 5:2716–2721.
70.
LiuK-Ket al.Covalent linkage of nanodiamond-paclitaxel for drug delivery and cancer therapy. Nanotechnology, 2010; 21:315106.
71.
ChouHH, WangKL, ChenCAet al.Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol., 2006; 101:423.
72.
GabizonA, MartinF. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs, 1997; 54,Suppl 4:15–21.
73.
AdnanA, LamR, ChenHet al.Atomistic simulation and measurement of pH dependent cancer therapeutic interactions with nanodiamond carrier. Mol Pharm., 2011; 8:368–374.
74.
KoletsaT, KotoulaV, KarayannopoulouGet al.EGFR expression and activation are common in HER2 positive and triple-negative breast tumours. Histol Histopathol., 2010; 25:1171–1179.
75.
XiaoZ, Levy-NissenbaumE, AlexisFet al.Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano., 2012; 6:696–704.
76.
RakhaEA, El-SayedME, GreenARet al.Prognostic markers in triple-negative breast cancer. Cancer., 2007; 109:25–32.
77.
DellianM, YuanF, TrubetskoyVSet al.Vascular permeability in a human tumour xenograft: Molecular charge dependence. Br J Cancer, 2000; 82:1513–1518.
78.
JangSH, WientjesMG, LuDet al.Drug delivery and transport to solid tumors. Pharm Res., 2003; 20:1337–1350.
79.
SchipperML, IyerG, KohALet al.Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small, 2009; 5:126–134.
